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Abstract
The member organizations of the Cytology Education and Technology Consortium believe there
are significant flaws in current cytology proficiency testing regulations. The most immediate needed
modifications include lengthening the required testing interval, utilizing stringently validated and
continuously monitored slides, changing the grading scheme, and changing the focus of the test
from the individual to laboratory level testing. Integration of new computer-assisted and located-
guided screening technologies into the testing protocols is necessary for the testing protocol to be
compliant with the law.
Preamble
In the following document, the Cytopathology Education
and Technology Consortium (CETC) states in detail its
concerns with technical and scientific aspects of the fed-
eral cytology proficiency testing (PT) criteria established
in 1992 regulations implementing the Clinical Laboratory
Improvement Amendments of 1988 (CLIA). The CETC con-
tinues to be concerned that the program has fundamental
flaws and therefore supports the larger pathology commu-
nity in urging HHS to suspend and halt further implemen-
tation of the program until a thorough re-evaluation of its
approach, relevancy and validity can be conducted. The
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procedures for evaluation of the quality of laboratory test-
ing should be developed in conjunction with knowledge-
able professional organizations; they should not be
relegated solely to implementation of the examination.
Also, certification examinations administered by perti-
nent medical specialty boards and allied health creden-
tialing agencies should be taken into account in
determining whether or not competence has been ade-
quately demonstrated. Our views, however, are not lim-
ited to those described in this communication. Some
members of the consortium believe strongly that adjust-
ing the current regulation will not by itself correct this
flawed program and that an alternative approach must be
developed that may require changes to the underlying
statute as well as changes to the regulation. The CETC
urges CMS to consider all necessary changes whether they
be regulatory or statutory in order to revise this program.
The CETC will be reviewing all the pertinent regulations
[1,2] and responding with detailed comments, which will
include justification and the impact of our suggested
changes.
Proficiency testing (PT) in gynecologic cytology has been
a controversial topic for many years. Though mandated by
the federal government seventeen years ago as part of the
Clinical Laboratory Improvement Amendment (CLIA
'88), it had been implemented in only one state prior to
2005. Challenges preventing widespread implementation
have included the inability to replicate normal working
conditions, the subjective nature of cytologic interpreta-
tion, absence of a "gold standard" against which test
results can be compared, and confidence that test per-
formance adequately correlates with proficiency and com-
petency of the practicing professional and improves
patient care. In addition, PT has been directed chiefly at
the level of the individual cytotechnologist and
cytopathologist, and has not addressed performance of
the entire laboratory or aspects of the Pap test process
other than microscopic evaluation.
In the fall of 2004, the Center for Medicare Services (CMS)
announced its approval of a proficiency test developed by
the Midwest Institute for Medical Education (MIME), and
its planned implementation in 2005 to fulfill the CLIA
mandate. Members of the Cytology Education and Tech-
nology Consortium (CETC), an organization composed
of representatives of the American Society of Cytopathol-
ogy, American Society for Clinical Pathology, the Ameri-
can Society for Cytotechnology, the College of American
Pathologists, the International Academy of Cytology and
the Papanicolaou Society of Cytopathology, met on
November 15, 2004 to discuss CMS's announcement. The
following are the science-based concerns identified by
CETC:
• The frequency of testing is excessive
• Validation of the test slides is inadequate since it is based
on the review of only three pathologists. Inadequate vali-
dation of test slides could lead to indiscriminate failure of
qualified, competent personnel.
• The scoring system and reporting terminology is
believed to be inappropriate and unfair. Though these
may reflect the current terminology used in Pap test
reporting, it does not reflect the clinical implications asso-
ciated with this terminology in modern practice, particu-
larly regarding recommended follow-up.
• The test does not consider common and important
aspects of modern gynecologic cytology practice such as
computer-assisted screening or location-guided screening.
• Testing is directed at the level of individuals instead of
the level of the laboratory as in all other proficiency test-
ing.
Discussion
Testing interval
The CETC recommends that the PT interval be lengthened
to five years for most cytology practitioners, rather than
the current one year test interval. There is no evidence to
suggest that cytology screening and interpretive abilities
deteriorate after a year. Cytology assessment is not at all
analogous to clinical laboratory PT. Clinical laboratory
testing results are very dependent on instrument calibra-
tion and reagents, which may vary significantly from lot to
lot, necessitating more frequent PT. Less frequent assess-
ment is appropriate for the well-trained cytology profes-
sional who is assessing cervical cytology slides on a regular
basis.
Certification organizations do not require annual testing
to maintain a valid certificate. The 24 medical boards
under the American Board of Medical Specialties imple-
mented the Maintenance of Certification initiative a few
years ago, and the recertification cycles for these boards
range from 6 to 10 years [3]. Test results do not show dete-
rioration during the ten (10) year period (personal com-
munication, M. Lunz). In between the formal
examination, board-certified physicians with time-limited
certificates are required to show evidence of continuing
education and performance improvement initiatives.
Cytology laboratories are already subject to many other
quality assurance and improvement requirements under
CLIA '88, which address daily quality screening practices.
The CLIA '88 legislation does not mandate a specific test-
ing interval, stating that such assessment should be "peri-
odic." As long as there are stipulations that individuals
new to practice be assessed within a certain time interval,CytoJournal 2006, 3:11 http://www.cytojournal.com/content/3/1/11
Page 3 of 8
(page number not for citation purposes)
a five-year interval for the great majority of competent
practitioners would satisfy the intent of the law.
Validation of slides
There is concern that the slides used in the MIME test are
not well validated. Validated slides are important for
meaningful PT. Despite the extensive training undergone
by all cytologists, significant interobserver variation in the
interpretation of gynecologic cytology specimens is well
documented in numerous studies over the past two dec-
ades. [4-7] Even experienced cytologists often show signif-
icant disagreement in their interpretations of some cases.
[8] This interobserver variation may affect the outcome of
(PT) in a manner unrelated to actual proficiency of exam-
ining slides. For example, a study by Valente and Schantz
[9] examined the reproducibility of PT in a workshop set-
ting. One slide with a reference interpretation of low-
grade squamous intraepithelial lesion (LSIL) was given
that interpretation by examinees 66.7% of the time,
whereas two other slides with the same reference interpre-
tation were given the that interpretation by examinees
92% and 94% of the time. This variation may be thought
of as representing differing levels of "difficulty" of the
cases. In order to be fair and valid, the slides and slide sets
presented to different individuals in a proficiency test
must be of equal difficulty. Section Sec. 493.945 of the
CLIA law specifically states:
"...test sets should be comparable so that equitable testing
is achieved within and between proficiency testing provid-
ers."
If test slides are not of equivalent difficulty, individual
competency assessment is unreliable or inconsistent. [10]
While use of a small number of experienced pathologists
to assign a reference interpretation for slides used in a PT
program is an appropriate part of the overall design of
such a program, it should not be the only criterion for
selection since interobserver variability amongst exami-
nees can still be quite significant. Once a preliminary ref-
erence interpretation is assigned, the difficulty of each
slide which will ultimately be included in a PT program
must be established by pilot testing, also known as field
validation. Field validation consists of statistical assess-
ment of the performance of each slide under actual testing
conditions. [11] As a practical consideration for a short
examination, all slides in each category should be of the
same difficulty, i.e. if there are two HSIL slides on an
examination, they should both meet the same validation
criteria. The examination should not have one slide which
field validated at 75% of responses concordant to the ref-
erence interpretation, and another of the same reference
interpretation, which validated at 90% concordance.
Slides used for PT should demonstrate that they perform
well (i.e., that they can be interpreted in a consistent man-
ner by a significant majority of practicing cytologists) in
pilot testing prior to inclusion in proficiency tests. Slides
that perform poorly may increase the margin of error of
the exam and adversely affect the precision of the pass-fail
decision made about candidates. [11] Use of unvalidated
slides decreases the likelihood of accurately detecting
individuals needing remediation, and increases the likeli-
hood of inconsistent and/or erroneous test outcomes,
which could lead to competent cytologists being penal-
ized.
Validation criteria must be stringent in order to minimize
the likelihood of spurious results. This is particularly
important with regard to HSIL slides since examinees will
fail the test if a single HSIL slide is missed. An example of
validation criteria used in an interlaboratory comparison
program recently published in the peer-reviewed litera-
ture by Renshaw [12] includes the following parameters:
1. There must at least 20 responses for each slide, to insure
a sufficiently large dataset on which to compute valida-
tion statistics.
2. Participants must respond in the correct series at least
90% of the time. (There were three "series" in this study a)
unsatisfactory, b) normal, infections, and reparative con-
ditions, and c) epithelial abnormalities and carcinoma.)
3. The standard error of this percentage must be 0.05 or
less.
Other criteria included specified rates of concordance to
the exact reference interpretation for the LSIL category.
The impact of the field validation process on the selection
of slides in the program is of interest. 31.8 percent of con-
ventional smears and 15.8 percent of ThinPrep slides with
a reference interpretation of LSIL, 9 percent of conven-
tional smears and 17.6 percent of ThinPrep slides with a
reference interpretation of high-grade squamous intraepi-
thelial lesion (HSIL) failed to achieve the program's crite-
ria for field validation. In addition, over 50 percent of the
slides of either type with a reference interpretation of
unsatisfactory failed to achieve the program's criteria for
field validation. The reference interpretations for all slides
in that study were first agreed upon by consensus of three
unmasked experienced cytopathologists as well as the
donor laboratory. In addition, slides with an interpreta-
tion of any SIL had histologic confirmation.
Another recent study by Renshaw has demonstrated that
the robustness of field validation criteria vary with differ-
ent reference interpretations. [13] The validation criteria
for herpes, trichomonas, squamous cell carcinoma, andCytoJournal 2006, 3:11 http://www.cytojournal.com/content/3/1/11
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adenocarcinoma were significantly more robust than the
criteria for the interpretations of NILM-NOS, LSIL, and
HSIL in that study. The robustness measurement is also a
surrogate marker for the ease of slide interpretation; in
other words, some reference interpretations are more eas-
ily arrived at than others. Differences in difficulty between
different reference interpretations must be taken into
account in the design of a proficiency test that is fair to all
participants. Examination sets should have a similar mix
of cases from the high and low robustness groups to avoid
having a wide variation in the overall difficulty of the test.
In conclusion, the inherent, well demonstrated interob-
server variability in the interpretation of Pap tests must be
taken into consideration in the design of a fair and valid
test. Field validation of the slides prior to their use in
graded test sets is mandatory for the test to be considered
acceptable to the CETC.
A related and important issue is that the validation status
of slides in a PT program must be continuously moni-
tored. Slides may become scratched or broken, cover slips
may partially detach, and stains may fade. The result of
these changes is that the performance of slides may dete-
riorate from acceptable to unacceptable over time. Slides
whose performance falls below the stated validation crite-
ria of the program should be removed from the program
and replaced with slides which have been field validated.
In addition, provision should be made in the regulations
for individuals who fail a test if the slide for any missed
question falls below the validation criteria during that
round of testing. Individuals in this situation should not
be penalized, and if retesting is deemed necessary, there
should be no additional cost to the affected individual or
his or her institution.
Proposed grading scheme
The CETC recommends changing the current grading
scheme. The grading scheme proposed under the rules
published in 1992 (Tables 1, 2) is based on a triage algo-
rithm in use at the time that had been in place since the
late sixties. [14] However, with the Bethesda 2001(TBS
2001) Workshop on terminology, [15,16] and the subse-
quent American Society for Colposcopy and Cervical
Pathology (ASCCP) consensus conference on manage-
ment of patients with Pap test abnormalities reported
using TBS 2001, the triage and management guidelines
have changed. [17] Under the old guidelines, patients
with low-grade lesions (LSIL/HPV/CIN I/mild dysplasia)
were often followed by repeat cervical cytology, whereas
those with high-grade lesions (HSIL/CIN II and above)
were triaged for colposcopy and biopsy. The current man-
agement guidelines are evidence-based as a result of our
better understanding of Human Papilloma Virus (HPV)
biology and the ASCUS Low-Grade Triage Study (ALTS).
[18-26] Data from the ALTS trial clearly demonstrated
that HPV positive ASC-US and LSIL carry about a 25% risk
of harboring a high-grade lesion and hence are referred for
immediate colposcopy and biopsy. The subsequent man-
agement depends primarily upon the findings from that
procedure although if the colposcopic and initial histo-
logic findings are negative, management following a Pap
test interpreted as LSIL is more conservative than it is with
one interpreted as HSIL.
Table 1: Point values (current)
Pathologist (Technical Supervisor) 10 Slide Test
Correct Response Examinee Response
A -UNSAT B -NEGATIVE C -LSIL D-HSIL
A -Unsat 10 0 0 0
B -Negative 5 10 0 0
C -LSIL 5 0 10 5
D -HSIL 0 -5 5 10
Table 2: Point values (current)
Cytotechnologist 10 Slide Test
Correct Response Examinee Response
A -UNSAT B -NEGATIVE C -LSIL D-HSIL
A -Unsat 10 0 5 5
B -Negative 5 10 5 5
C -LSIL 5 0 10 10
D -HSIL 0 -5 10 10CytoJournal 2006, 3:11 http://www.cytojournal.com/content/3/1/11
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The College of American Pathologists (CAP) PAP program
has been in existence since 1989. The CAP PAP data have
demonstrated that it is very difficult to find slides that
achieve unanimous consensus as LSIL (low-grade
lesions). [4] Even when three experts on the CAP Cytopa-
thology Resource Committee agree with a biopsy-proven
case of a LSIL, the slide does not reach field validation
from participants approximately 20% of the time. [12]
The ALTS trial similarly demonstrated that only 69% of
original LSIL interpretations by clinical centers were
upheld by the Pathology QC reviewers. [25] LSIL and
HSIL are reported as distinct interpretations in TBS 2001,
and populations of patients in these two categories do
show different follow-up profiles. However, it is recog-
nized that separating these squamous abnormalities in
individual cases is not an exact science. Therefore, colpos-
copy is recommended for both LSIL and HSIL. Hence, the
grading scheme penalizing pathologists 5 points for not
distinguishing LSIL from HSIL is outdated and excessive.
The study by Valente and Schantz[9] identified some of
the inequities in the grading scheme. The passing scores
found in their workshop setting were comparable to the
first administration of the Maryland Proficiency Test. [27-
29] The differences in pass rates between technologists
and pathologists seemed attributable to the grading
scheme that allows partial or full credit to the technologist
while penalizing the pathologist. Technologists receive
full credit for identifying any abnormality (choices C or
D) without being required to separate LSIL and HSIL
(similar to CAP PAP and American Society for Clinical
Pathology (ASCP) STAR scoring), while the pathologists
lose half of the points allowed. While obvious LSIL and
CIS/Cancer cases performed reasonably well in a work-
shop setting, some cases were close enough to the border
between LSIL/CIN I and HSIL/CIN II to show poor sepa-
ration of the C and D categories; the result was that some
slides had about 60% correct answers while others had
80–90% consensus.
Based on the information above, we propose only a small
penalty of one quarter of the points allowed when pathol-
ogists give an LSIL response for an HSIL case or vice versa.
Another area of obvious concern centers around the "A"
choice- Unsatisfactory (Table 1). Only VERY obvious
unsatisfactory cases elicited the desired response with
only 60% of respondents in Valente and Schantz's [9]
study getting the correct answer. In the CAP PAP program,
less than 50% of the slides accepted into the program
using the three Board certified anatomic pathologists' rule
achieved field validation. [12] In addition, a considerable
number of slides accepted as negative/NILM are reported
as unsatisfactory by one or more participants. Based on
TBS 2001 and ASCCP management guidelines, an unsat-
isfactory interpretation results in immediate repeat, and
there is minimal detrimental effect to the patient if a neg-
ative "B" slide is reported as unsatisfactory. This consists
chiefly of the inconvenience of having to return for a
repeat test. Hence, there should be no penalty in the pro-
ficiency test if a negative slide is reported as unsatisfactory.
However, the reverse situation, in which a field-validated
Table 3: Point values (proposed)*
Pathologist (Technical Supervisor) 10 Slide Test
Correct Response Examinee Response
A -UNSAT B -NEGATIVE C -LSIL D-HSIL
A -Unsat 10 0 0 0
B -Negative 10 10 0 0
C -LSIL 5 0 10 7.5
D -HSIL+ 0 07 . 5 10
Table 4: Point values (proposed)*
Cytotechnologist 10 Slide Test
Correct Response Examinee Response
A -UNSAT B -NEGATIVE C -LSIL D-HSIL
A -Unsat 10 0 5 5
B -Negative 10 10 5 5
C -LSIL 5 0 10 10
D -HSIL+ 0 0 10 10
*CETC believes that stringently field validated slides are mandatory for a test to be fair and valid.CytoJournal 2006, 3:11 http://www.cytojournal.com/content/3/1/11
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unsatisfactory slide is reported as negative/NILM should
carry a penalty, as such a patient would not receive early
repeat.
Finally, we feel there is no justification that a false nega-
tive response of negative for an HSIL or cancer slide be
given greater weight (minus 5) than a false positive
response of HSIL for a negative slide (Table 1). Both
pathologists and cytotechnologists should be given a
score of zero when they give a negative response for an
HSIL/cancer D category slide.
Based on the above reasoning and the published papers
listed below, we propose the modification (Tables 3, 4) to
the grading scheme to make it current with the triage algo-
rithm and fair to the participants. Table 3, 4 show the pro-
posed point values for a ten question test. Proportional
changes should be made in the point values for a 20 ques-
tion test.
New technologies
New technologies such as computer assisted and location
guided screening have become available since the specifi-
cations of the test were initially published. In an increas-
ing number of laboratories use of these technologies is
routine, and screening of conventional Pap smears in the
traditional manner is no longer performed. Testing of
such laboratories in the manner described in the current
regulations is totally inconsistent with the CLIA law stat-
ing:
"...swith such testing to take place, to the extent practica-
ble, under normal working conditions."
The regulations and need to be revised to accommodate
laboratories in which the use of these new technologies is
"normal working conditions." Furthermore, the testing
scheme should be designed in such a way that new tech-
nologies which come into use in the future, such as digital
imaging, can be more readily accommodated. This should
include technologies used in practice and in educational
testing.
Individual testing
One of the most troubling aspects of the statute is the
requirement that cytotechnologists and pathologists be
tested individually. While all other general proficiency
testing under CLIA is directed toward measuring results at
the laboratory level, this provision departs from that
approach and singles out individuals. In many if not most
laboratories, cytotechnologists and pathologists have the
opportunity to consult their colleagues if they feel uncer-
tain regarding the most appropriate interpretation of the
slide. For this reason, CLIA's primary focus on laboratory
proficiency testing is well placed. While we certainly rec-
ognize that the statutory language governing PT for gyne-
cologic cytology mentions testing of individuals, it is
equally important to note that language also specifies that
the Secretary should establish quality assurance standards
that "assure consistent performance by laboratories of
valid and reliable cytological services...with such testing to
take place, to the extent practicable, under normal work-
ing conditions." In our estimation, "normal working con-
ditions" can be reflected in this examination only by
allowing the collaborative team approach that is a funda-
mental aspect of the laboratory environment and most
pathology practices. The regulation's premise that individ-
uals conducting laboratory work are doing so in isolation
and making determinations alone is false for most practi-
tioners. Any PT program seeking to adequately assess true-
to-life results must reflect this workplace reality in its test-
ing approach. We believe that laboratory-level testing is
both permitted under the law and is a better approach to
ensuring quality laboratory results, and is more reflective
of how Pap tests are performed in laboratories. The advan-
tage of this approach is that the functioning of the labora-
tory quality assurance processes is also evaluated. Quality
assurance procedures should allow any underperforming
individuals to be detected by the laboratory. In fact,
although the CLIA statute requires "periodic confirmation
and evaluation of the proficiency of individuals involved
in screening or interpreting cytological preparation..." it
does not specify the manner in which this task is to be
accomplished. This suggests that the proficiency of indi-
viduals need only be periodically confirmed and evalu-
ated and that formal enrollment of the individuals in a
proficiency testing program, in lieu of laboratory enroll-
ment in such a program, would be unnecessary.
Summary
The member organizations of the CETC feel strongly that
there are significant flaws associated with the proposed
proficiency test and its implementation. The most imme-
diate modifications include lengthening the required test-
ing interval, utilizing stringently validated and
continuously monitored slides, changing the grading
scheme, and changing the focus of the test from individu-
als to laboratory level testing, as described herein. Integra-
tion of new computer-assisted and location-guided
screening technologies into the testing protocol is neces-
sary for the testing program to be compliant with the cur-
rent CLIA law. The regulation also needs to be flexible
enough to accommodate new technologies that are imple-
mented in laboratory practice, education, and administra-
tion of the test. The changes recommended in this
document address the most immediate technical and sci-
entific concerns with the current implementation of pro-
ficiency testing for gynecologic cytology. The CETC will be
submitting a subsequent document following full reviewCytoJournal 2006, 3:11 http://www.cytojournal.com/content/3/1/11
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of the current regulations with recommendations for
changes, justifications, and impact.
The following organizations endorse this document:
American Society of Cytopathology
International Academy of Cytology
American Society for Clinical Pathology
Papanicolaou Society of Cytology
American Society for Cytotechnology
The College of American Pathologists, respectfully,
declines to endorse this document at this time but it sup-
ports the underlying criticisms of the existing regulatory
framework of cytology PT program. The CAP believes that
an alternative approach to the program must be devel-
oped to replace the existing program and that such an
alternative will likely require statutory and regulatory
modifications of CLIA.
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